agent 47 Antinuclear antibodies 191 Antithyroid antibodies 191 Apoptosis 296 Areola 73 Arthropathy 371 Atopic dermatitis 356 -eczema 231 Autoimmune disease 191 Baboon syndrome 258 Bacterial infection 341 Barrier 135 Bathwater delivery 106 Behçet disease 15, 140 Belanyx 313 Blaschko lines 60, 72, 373 Blood transfusion 20 Bullous pemphigoid 253 --antigen 180 253 Butcher 341 C1 inhibitor antibodies 227 c-myc oncogene 290 Cancer Registry Data 201 Carcinogenicity 106 Carcinoma, apocrine 332 --ductal 332 --skin 332 -, basal cell 119 -, cervical 171 -, cutaneous apocrine ductal 332 -, squamous cell 208 Cardiac disorder 3 Castleman disease 63 Ceftriaxone 25 Cell adhesion molecules 158

Bagot, M., Créteil, France Baran, R., Cannes, France Barker, J., London, United Kingdom Bastuji-Garin, S., Créteil, France Baudraz-Rosselet, Fl., Lausanne, Switzerland Beani, J.C., Grenoble, France Becker, D., Mainz, Germany Berardesca, E., Pavia, Italy Bernard, P., Reims, France Bernengo, M.G., Torino, Italy Black, M.M., London, United Kingdom Boisnic, S., Paris, France Bonifazi, E., Bari, Italy Bonnetblanc, J.M., Limoges, France Borradori, L., Genève, Switzerland Bos, J.D., Amsterdam, The Netherlands Böni, R., Zürich, Switzerland Braun, R.-P., Geneva, Switzerland Brenner, S., Tel Aviv, Israel Bruynzeel, D.P., Amsterdam, The Netherlands Bullani, R., Genève, Switzerland Burg, G., Zürich, Switzerland Büchner, S.A., Basel, Switzerland

BACKGROUNDRetinoids were shown to be effective in the treatment of both oral and cutaneous forms of lichen planus.OBJECTIVEConfirm the beneficial effect of low doses of oral tretinoin in lichen planus.METHODSEighteen patients with lichen planus were treated in an open study for up to 19 months. Efficacy and safety data were recorded.RESULTSComplete remission was observed in 13 (72%) and marked improvement in 4 (22%) out of 18 patients. Six patients showed moderate and 12 had no side effects.CONCLUSIONTretinoin is a valuable drug when given at low doses to patients with lichen planus who failed to respond to other therapies.

Background: 9-cis-Retinoic acid (9-cis-RA) is as active as 13-cis-retinoic acid (13-cis-RA) in inhibiting the proliferation of cultured human sebocytes and in reducing the size of sebaceous glands of hamsters. Objective: Evaluate the anti-acne effect of 9-cis-RA compared to that of 13-cis-RA in a pilot study. Methods: Four young male patients with acne were treated in an open study consecutively with 9-cis-RA and 13-cis-RA given at similar doses. Results: No beneficial effects were observed with 9-cis-RA in any of the patients whereas all responded favorably to 13-cis-RA. Conclusion: For the two retinoids tested, the anti-acne effect correlates with the sebosuppressive effect in humans.